The informed road map to prevention of Alzheimer Disease: A call to arms
Open Access
- 21 July 2021
- journal article
- review article
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 16 (1) , 1-19
Abstract
Alzheimer disease (AD) prevention trials hold the promise to delay or prevent cognitive decline and dementia onset by intervening before significant neuronal damage occurs. In recent years, the first AD prevention trials have launched and are yielding important findings on the biology of targeting asymptomatic AD pathology. However, there are limitations that impact the design of these prevention trials, including the translation of animal models that recapitulate key stages and multiple pathological aspects of the human disease, missing target validation in asymptomatic disease, uncertain causality of the association of pathophysiologic changes with cognitive and clinical symptoms, and limited biomarker validation for novel targets. The field is accelerating advancements in key areas including the development of highly specific and quantitative biomarker measures for AD pathology, increasing our understanding of the course and relationship of amyloid and tau pathology in asymptomatic through symptomatic stages, and the development of powerful interventions that can slow or reverse AD amyloid pathology. We review the current status of prevention trials and propose key areas of needed research as a call to basic and translational scientists to accelerate AD prevention. Specifically, we review (1) sporadic and dominantly inherited primary and secondary AD prevention trials, (2) proposed targets, mechanisms, and drugs including the amyloid, tau, and inflammatory pathways and combination treatments, (3) the need for more appropriate prevention animal models and experiments, and (4) biomarkers and outcome measures needed to design human asymptomatic prevention trials. We conclude with actions needed to effectively move prevention targets and trials forward.Keywords
Funding Information
- National Institute on Aging (U01AG042791, R1AG046179, R01/R56 AG053267, U01AG059798)
This publication has 162 references indexed in Scilit:
- Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation CarriersScience Translational Medicine, 2013
- Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β PeptideThe Journal of Neuroscience, 2012
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic reviewBMJ Open, 2012
- Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the LiteratureJournal of Neuropathology & Experimental Neurology, 2012
- The projected effect of risk factor reduction on Alzheimer's disease prevalenceThe Lancet Neurology, 2011
- Accumulation of intraneuronal Aβ correlates with ApoE4 genotypeActa Neuropathologica, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- APOE genotype-specific differences in the innate immune responseNeurobiology of Aging, 2009
- No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled TrialPLOS ONE, 2008